Value proposition

A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line)

Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a French-Belgian biotech company that develops an innovative class of active immunotherapies to treat cancers. This cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy. PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors.

PDC*line offers unique advantages:
- PDC*line is a professional and universal antigen-presenting cell much more potent than conventional (myeloid) Dendritic cells;
- unlike conventional autologous Dendritic Cells, PDC*line is very easy to expand in large quantities in bioreactors (no need of maturation factors) and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years.
- The off-the-shelf product is thawed and injected to treat any patients with a cancer type expressing the selected antigens and expressing HLA-A2. Of note, different HLA may be used or added to extend the target population.
- The approach is very versatile and applicable to any cancer type.

Based on a first-in-human phase Ib study in melanoma, PDC*line Pharma focuses on the development of a clinical candidate for lung cancer (PDC*lung) and neoantigens (PDC*Neo).

The company regroups a team of 42 persons led by Eric Halioua (CEO) and raised close to 61M€ in equity and loans since its foundation.

March 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 108M€ (123M$) plus significant tiered royalties on net sales in Asia.

Cancer immunotherapy, Therapeutic vaccines, Clinical development, Plasmacytoid Dendritic Cells, and neoantigens